Introduction
Since its discovery in 1998 1 the phenomenon of RNA interference (RNAi), that is sequence-specific silencing of a gene occurring upon the introduction or endogenous expression of homologous double-stranded RNA(dsRNA), has been observed in a wide variety of eukaryotes. This phenomenon that ultimately leads to a strong suppression of target gene expression (i.e. 'knockdown') can involve different mechanistic pathways depending on the organism and on the nature of the dsRNA trigger. 2 In 2001, the design of short (21-23nt) dsRNAs (small interfering RNAs: siRNAs) allowed to apply successfully RNAi to mammalian cells. 3, 4 Subsequently, plasmid and viral vectors expressing structurally related interfering dsRNA molecules, the short hairpin RNAs (shRNAs) and microRNAs (miRNAs) were developed and have paved the way to extensive analyses of gene function through RNAi-based reverse genetics. 5, 6 Chemically synthesized siRNAs have also been proposed as powerful reagents for therapeutic gene silencing owing to their great specificity and efficiency, their apparent lack of toxicity and their usually moderate propensity to trigger nonspecific gene silencing and/or interferon-related responses in the cell (the so-called 'offtarget' effects). [7] [8] [9] Several applications of siRNA therapeutics are currently under clinical development. 7, 10 The applicability of this approach to humans is further supported by recent data reporting the establishment of an efficient and long-lasting gene silencing in nonhuman primates upon systemic delivery of liposome-encapsulated siRNAs. 11 Different complementary approaches are currently developed in rodents to increase the in vivo stability of the siRNA molecule, to target it to the correct tissue and to facilitate its cellular uptake. These include chemical modification of the silencing RNA 10 packaging into protective particles 12, 13 and conjugation to cellspecific ligands or antibodies. 14, 15 Nevertheless, the further use of siRNA as therapeutic molecules will mostly rely on the development of efficient in vivo delivery methods, which remains by far the major challenge in this field. 8, 12, 16, 17 Among the numerous potential therapeutic applications of RNAi, the silencing of genes involved in the promotion or maintenance of tumorous growth appears as a very attractive additional approach to conventional chemotherapy for cancer treatment. 7, 18 However, few data have been published reporting the successful use of siRNA for gene silencing in developing tumors in vivo in rodent model systems. 14, [19] [20] [21] [22] [23] [24] Surprisingly, Filleur et al. 22 found that in mice direct microinjection of the siRNA solution into the tumor was ineffective whereas systemic administration methods induced significant gene knockdown in the tumor tissue. In contrast, Takahashi et al. 23 suggested that effective gene suppression could be obtained after direct intratumoral microinjection of the siRNAs followed by in situ electroporation. Electric pulses (EP) are indeed known to strongly stimulate cell uptake of various drugs and molecules showing intrinsically very poor cellular crossing abilities. The exact mechanism leading to enhanced intracellular nucleic acid delivery remain unclear but may involve, at least in vitro, the induction of physical interactions with the compound and the cell membrane followed by a progressive intracellular release into the cytoplasm. 25 In vivo, EP have been extensively used for drug and plasmid delivery in a large number of organs and tissues. [26] [27] [28] In addition, the delivery of molecules can be restricted to the volume where the electric field is generated. Also, very few side effects have been reported for these treatments thus emphasizing the inocuity of this physical method for clinical use and different projects attempting to develop electrochimiotherapy and electrogenotherapy (EGT) to enhance delivery of drugs and nucleic acids, respectively, are currently underway (e.g. ESOPE and Angioskin European projects, Inovio Biomedical Corp.).
In rodents, EP have been used to deliver siRNAs in various organs such as skin, 29 eyes, 30 brain, 31 muscles, 32, 33 joint tissue 34, 35 and kidney. 36 However, delivery of large nucleic acids (plasmids) have been found to be poorly efficient in solid tumors. [37] [38] [39] To assess the relative contribution of electrical treatment to siRNA-mediated endogenous gene silencing in solid tumors we generated B16-F10 mouse melanoma cell lines stably expressing an enhanced green fluorescent protein (EGFP). The extent of EGFP gene suppression in subcutaneous B16-EGFP tumors was subsequently monitored over time in the living animal by whole-body fluorescence imaging. Digitized observation by a highly sensitive CCD camera allowed a time-lapse analysis of reporter gene expression over a long period. EGFP knockdown was observed far more than 3 days after one single injection of moderate amounts of siRNA followed by electropulsation. The inhibition of the EGFP gene was also measured using flow cytometry analysis of cells isolated from tumors and confirmed by quantitative RT-PCR, thus demonstrating that the observed inhibition was owing to siRNAmediated mRNA degradation.
Results

Intra-tumoral electricallymediated siRNA delivery
We designed an experimental system allowing to test whether electrical treatment could significantly enhance the delivery of unmodified siRNA to solid tumors in mice as well as to follow the extent of gene silencing over time in the living animals. For this, B16-F10 melanoma cells stably expressing EGFP reporter gene under nonselective growth conditions were isolated following infection by an EGFP-expression retroviral vector. One of these cell lines (B16-F10 GFP) was subsequently inoculated into CL57bl/C mice and subcutaneous tumors were allowed to form for 8 to 10 days. In vivo digital imaging was subsequently used to evaluate the size of fluorescent tumors and to quantify GFP fluorescence intensity changes over time (Figures 1 and 2) .
When tumors reached an average diameter of 5-7 mm a siRNA directed against the EGFP gene (egfp22 siRNA 3 ) or an unrelated non silencing siRNA (P76 siRNA) were injected slowly into the mouse tumor. Around 30 s after injection, plate parallel electrodes were put in direct electric contact with the shaved skin using a conducting paste and the tumor was electropulsed using squarewaved pulses (pulse duration; 5 ms; frequency of pulses, 1 Hz) and a pulse electrical condition of 800 V/cm. These conditions were chosen as they were previously shown to induce in vivo reporter gene expression in solid tumors with no tissue damage. 38, 39 As reported previously, a muscle contraction was observed when the electric field was applied. Neither local burns or edema nor short or long-lived loss of functions were observed.
When the egfp22 siRNA was electrotransferred (anti-GFP+EP), a significant decrease in the GFP fluorescence of the tumor was observed by direct imaging on the animal (Figure 1 ) and quantification of the fluorescence levels ( Figure 2 ) within 2 days following the treatment. The decrease was maximal from days 2-4 (reduction to about 30% of the physiological saline control). This was in agreement with the reported half-life of the GFP of 24 h in cells. A noticeable increase of EGFP fluorescence level was, however, observed at day 5, indicative of a clear attenuation of the RNAi effect at this time point (Figure 2a) . The presence of an RNase inhibitor in the injection buffer appeared important, as only a slight, not statistically significant decrease of the fluorescence was obtained when the RNA-protective agent was absent (data not shown). The decrease of GFP fluorescence observed upon egfp22 siRNA electrotransfer was not observed in the different control groups (Figure 2b) . Indeed, if an unrelated non-silencing siRNA (P76 siRNA) was electrotransferred, no changes of EGFP expression compared to the other controls could be detected. As expected the electrical treatment itself (phosphatebuffered saline (PBS) +EP) had no effect on the GFP expression in the tumor. More interestingly, if no EP were applied after injection of the egfp22 siRNA (anti-GFPÀEP) no statistically significant reduction of the GFP expression relative to controls could be observed. This demonstrated that the electrical treatment of the injected tissue was essential to the efficient delivery of the siRNA to tumor cells. The growth of the tumors was not affected by any treatment (intratumoral injection of the siRNA and/or EP). At day 4 after the treatments, some of the tumors showed some necrotic areas in their middle. This phenomenon is inherent to the type of tumors formed by the B16 cell line and was observed in all the different groups of treatments.
Additionally, fluorescence imaging allowed us to visualize all nodules that form the whole tumor. An injection targeted to defined nodules was possible. In this case we noticed that only those nodules, which were injected with the egfp22 siRNA and subsequently electropulsed showed a fluorescence decrease. Moreover, no decrease was observed in the small nodules occasionally developing close to the tumor and which were not injected at day 0 (Figure 1b, arrows) . This indicated that the action of the siRNA molecules remained restricted to the region that was treated both by the injection and the electrical treatment.
RNA extraction and quantitative real-time PCR
GFP fluorescence is the final product of a long and complex pathway involving transcription, translation and post-translational modifications. It is known that the formation of the GFP final fluorophore, a posttranslational modification resulting from spontaneous cyclization and oxidation of the protein's amino acids, Electrically mediated gene silencing in tumors M Golzio et al Ser 65 (or Thr 65 )-Tyr 66 -Gly 67 -, requires molecular oxygen and it has been shown by Coralli and coworkers, 40 which under hypoxic condition the level of GFP fluorescence was decreased whereas no significant change in the mRNA level was noticed. To demonstrate that this phenomenon of fluorescence decrease under hypoxia was not at the origin of the effects we observed, but was the result of RNAi-mediated inhibition of gene expression we performed quantitative real-time PCR to evaluate the EGFP mRNA content of the treated tumors.
At day 4, mice were killed and tumors were processed for RNA extraction. Quantitative RT-PCR using GeNorm analysis revealed a 52% reduction of the EGFP mRNA content of the tumors electrotransferred with the egfp22 siRNA in comparison with the physiological saline control whereas no significant differences in EGFP mRNA levels could be observed with the other treatments ( Figure 3 ). These data demonstrated that the drop in GFP fluorescence observed after the electrotransfer of the egfp22 siRNA truly originated from a siRNAmediated degradation of the EGFP mRNA. showed that direct intratumoral injection of an siRNA directed against luciferase in rat cJ4 tumor xenografts was ineffective, whereas three systemic administration procedures led to significant downregulation of this target gene. Although systemic delivery of siRNAs by intraperitoneal or intravascular administration may be a very promising therapeutic approach for tumor treatment, especially in the case of metastatic tissues this approach may require large amounts of siRNA and may be inapplicable for therapeutic siRNAs inducing systemic side effects and/or when siRNA delivery to certain tissues has to be avoided. Aharinejad et al. 19 reported partial inhibition of expression of colony-stimulating factor-1 and its receptor in MCF-7 xenografts upon injection of naked siRNAs. This, however, required five successive injections of siRNA over a 15 days period, again suggesting that delivery to tumor cells may be poorly efficient. Takei and coworkers 20 used complexation to atecollagen to stabilize and assist delivery of siRNA directed against vascular endothelial growth factor to human PC-3 carcinoma implants in mice. Leng and Mixson 21 succeeded in reducing tumor growth in human breast cancer MDA-MB-435 xenografts upon repeated injection of siRNAs directed against raf-1 kinase and conjugated with histidine-lysine polymers. However, the extent of gene knockdown in the tumors was not evaluated.
EP induce a major reorganization of the lipid bilayer in membranes of cells leading to a transient 'permeabilized' state. 25 This physical technique has been previously used by different groups including ours to locally deliver siRNAs in various tissues. [29] [30] [31] [32] [33] [34] [35] [36] As reported previously we observed that the electrical treatment itself had no detectable effect on tumor growth. Takahashi and coworkers 23 recently found that EP following injection in mouse melanoma tumors slightly improved the uptake of a plasmid encoding luciferase and subsequently attempted this approach for treatment of the tumors with siRNAs or plasmids encoding shRNAs. However, the contribution of electrical treatment to plasmid delivery in the tumors appeared moderate as reported previously [37] [38] [39] and this point was not addressed with the siRNA molecules.
In this study, we defined an experimental system allowing to visualize and quantify the downregulation of a constitutively expressed EGFP reporter gene in subcutaneous B16-F10 mouse melanoma tumors using non-invasive in vivo fluorescence imaging. This allowed us to follow in situ the kinetics of siRNA-mediated inhibition of gene expression, the topology of the effect in the tumor and to test the impact of electrical treatment on the establishment of gene knockdown. Here we showed that in this model electrical treatment was essential to intracellular uptake of the siRNA following direct intratumoral injection. As reported previously by Filleur 22 with the luciferase reporter gene in cJ4 tumors, no significant reduction of EGFP expression in the tumor could be detected after injection of the egfp22 siRNA directed against EGFP at any time point (Figures 1 and  2b) . Furthermore, no localized drop of fluorescence was apparent in the analyzed tissues. A specific and significant silencing of EGFP could be observed in the developing tumor only after electrotreatment. This inhibition was established 2 days after treatment following a single injection of siRNA, appeared distributed to the whole siRNA-impregnated tumor tissue and remained maximal until day 4.
By performing quantitative real-time reverse transcription PCR on RNA purified from treated tumors we confirmed that the decrease of EGFP fluorescence was correlated with a specific RNAi-mediated degradation of the EGFP mRNA leading to a 50% reduction of its steady-state level (Figure 3) . The inhibition of EGFP reporter expression was further analyzed by flow cytometry analysis of B16-EGFP cells extracted from treated tumors (Figure 4 ). This revealed that the average 60% drop of fluorescence observed by in vivo imaging of tumors following electrotreatment with the egfp22 siRNA originated from a reduction in the percentage of cells expressing EGFP, whereas the mean fluorescence value of the remaining EGFP positive cells was apparently unaffected. This suggested that the partial knockdown of EGFP in the tumor was not the result of a poor intracellular activity of the gfp22 siRNA itself in the B16-EGFP cells but was rather owing to delivery of this molecule to only a fraction of the cells forming the tumor. This again underlines intracellular access as the major hurdle to siRNA action in vivo. In situ fluorescence imaging allowed us to observe occasionally B16-EGFP nodules growing in close proximity of the treated tumor. These nodules appeared strongly fluorescent even in mice electropulsed with the egfp22 siRNA (Figure 1 ). This lack of EGFP inhibition in surrounding nodules indicated that the action of the siRNA was controlled by both the injection and the electrical treatment.
In conclusion, our results showed that efficient RNAimediated inhibition of gene expression in solid tumors can be achieved by using a non-systemic approach of delivery based on direct intratumoral injection of siRNAs followed by localized electrotreatment and revealed that this second step appears essential to the success of this approach. This may be advantageous in cases were spatially controlled siRNA silencing is required.
Materials and methods
Cell lines
B16-F10 mouse melanoma cells and their EGFP-expressing derivatives were maintained in Eagle's minimum essential medium (EMEM; Gibco-Invitrogen, Carlsbad, CA, USA) with 10% fetal calf serum (Gibco), penicillin (100 units/ml) (Gibco-Invitrogen), streptomycin (100 mg/ ml, Gibco-Invitrogen) and L-glutamine (0.58 mg/ml; Eurobio, France) in a 5% CO 2 humidified incubator at 371C (Jouan, St Herblain, France).
Retroviral vector and in vitro transduction
MFG-eGFP
41 is a retroviral vector encoding the EGFP under the control of a 5 0 long terminal repeat (LTR). 293T cells were generously provided by the Genethon (Evry, France). Generation of 293T-MFGeGFP and preparation of high titer retroviral vector pseudotyped with VSV-G protein have been described previously. 42 Briefly, 293T cells were transiently transfected using the calcium 
Mouse tumor model
Female C57Bl/6 mice were obtained from Rene Janvier (St Isle, France) and were subjected to an adaptation period of at least 10 days before experiments. They were maintained at constant room temperature with a 12-h light cycle in a conventional animal colony. The mice were 10-14 weeks old at the beginning of the experiments, weighing 20-25 g.
Tumors were implanted subcutaneously in the right flank of the mice by inoculation of 1 Â 10 6 B16F10-EGFP cells in PBS and grown to a size of 5-7 mm in diameter. Procedures were performed with approved protocols, in accordance with the French CNRS and EU commission regulations for laboratory animals' care. 
In vivo electropulsation
Fifty microlitres of saline solution (i.e. PBS containing 40 units of the RNAse inhibitor RNAsin (Promega, Madison, WI, USA) and either 12 mg of egfp22 or of p76-siRNA were slowly injected (about 15 s) with a Hamilton syringe through a 26G needle (Hamilton, Bonaduz, Switzerland) into the tumor, under isoflurane anesthesia.
In the control conditions, the volume of siRNA was replaced by the siRNA suspension buffer to keep the injection conditions similar. Thirty seconds after injection, an electric pulsation was applied. Plate parallel electrodes (length 1 cm, width 0.6 mm, interelectrode distance 6 mm) (IGEA, Carpi, Italy) were fitted around the tumor. The tumor was previously shaved with a cream (Veet, Reckitt & Colman, Massy, France). A good electric contact was obtained between the skin and the electrodes using a conducting paste (Eko-gel, Egna, Italy). Electrical parameters were defined by taking into special consideration pulse duration which appears a critical parameter for nucleic acid electrotransfer 38 as well as using pulses with reverse polarities that help electrodelivery by taking advantage of the vectorial character of the electric field. 43 The tumor was electropulsed with selected parameters using the PS 10 CNRS Electropulsator (Jouan, St Herblain, France). Squarewaved pulses were delivered as described previously. 38 Voltage (480 V), pulse duration (5 ms) and frequency of pulses (1 Hz) were all preset on the Electropulsator. A train of four pulses plus four additional pulses in the reverse polarity was delivered. All parameters were monitored on line with an oscilloscope (Metrix, Annecy, France). An electronic switch cutting the pulse as soon as its intensity reached 5 A protected against current surge.
Non-invasive stereomicroscopy fluorescence imaging in live animals
GFP expression in the tumor cells was detected directly through the skin on the anesthetized animal by digitized fluorescence stereomicroscopy. This procedure allowed the observation of GFP expression on the same animal during several days. Mice were anesthetized by intraperitoneal injection (10 ml/kg) of physiological saline containing 1 mg/ml xylasine and 5 mg/ml ketamine. The animals were kept under anesthesia during the whole procedure.
High-magnification images were obtained with an epifluorescence stereomicroscope using the 0.8 magnification (Leica MZFL III, Germany) and a cooled CCD camera (Roper Coolsnap fx) as described previously. 32 A 15 mm 2 part of the animal was observed, which was suitable to observe the whole tumor. Camera was driven by the MetaVue software 2.6 (Molecular Devices Corporation, Downington, PA, USA) from a Dell computer. The exposure time was set at 1 s. with no binning. The fluorescence excitation was obtained with a Mercury Arc lamp (HBO, Osram, Germany) and a GFP filter (Leica Microsystems, Mannheim, Germany) for emission. The GFP fluorescence from the tumor was quantitatively evaluated at different days. A transmission picture and a picture with GFP filter were taken on each tumor.
Analysis of numerical images
From the transmission picture, the tumor was located and manually gated to give the region of interest (ROI). On the picture taken with the GFP filter, the mean fluorescence in the gated area (whole tumor) was quantitatively estimated. Another ROI was defined next to the tumor to determine the mean fluorescence background on the skin and normal tissue. In our experiments, the background fluorescence was systematically removed even if it was sufficiently low not to interfere with our quantification, when GFP emission was present.
Numerical values obtained by Metavue analysis software were transferred to Microsoft Excel and used for data analysis. To quantify the knockdown induced by the delivery of the siRNAs in each tumor, the fluorescence intensity of the tumor on day 0 (i.e. before the treatment) was set as the 100% value for each animal and the 'relative fluorescence on day X 0 -values were in reference 
RNA extraction and quantitative real time PCR
RNA was purified by using the RNeasy Protect mini kit (Qiagen, Valencia, CA, USA). Immediately after harvesting tumor tissues were submerged in the RNAlater stabilization reagent and stored at 41C for at least 24 h. For RNA extraction, stabilized tissues were quickly transferred in chilled RLT buffer and immediately disrupted using a Bio101 FastPrep FP120 tissue disruptor (Qbiogene, Morgan Irvine, CA, USA) for two cycles of 20 s at a setting of 6.0 using lysing matrix D Total RNA was purified according to Qiagen's protocol and possible traces of contaminating genomic DNA eliminated using the TURBO DNA-free kit (Ambion, Austin, TX, USA). Quality of the RNA was controlled by agarose gel electrophoresis. cDNAs were produced from 5 mg of total RNA by a reverse transcription at 551C for 40 min using random hexamer primers followed by treatment with RNase H using the Thermo-Script RT-PCR system (InVitrogen, Carlsbad, CA, USA). Quantitative real-time PCR analyses were performed on the cDNAs with 300 nM of each primers into the 1 Â SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) using an Abi Prism 7000 Sequence Detector systems (Applied Biosystems). For each sample, measurements of gene expression were carried out in triplicate in 96-well reaction plates. The geNorm 44 VBA applet for Microsoft Excel was used to determine the most stable reference mRNA transcripts using a set of seven PCR primer couples targeting different mouse housekeeping genes. EGFP expression values were normalized by a factor calculated by geNorm from the three most stable reference genes: b-glucuronidase, the YWHAZ tyrosine 3-monooxygenase and b-actin-2. All PCR primers used in this study were validated for quality of the amplification by controlling the dissociation curves of the products and amplification efficiencies. The primers used for EGFP amplification were primers EGFP214f (5 0 -GCAGTGCTT CAG CCG CTA C-3 0 ), and EGFP309r (5 0 -AAG AAG ATG GTG CGC TCC TG-3 0 ) which were previously described by Klein and coworkers. 45 Other primers were designed using the Primer Express software (Applied biosystems). The sequences of the PCR primers for the selected housekeeping reference genes are the following: b-glucuronidase; b-glucF, 
Statistical analyses
For each condition, 4-9 animals were treated. Only one tumor was implanted per mouse to avoid possible cross reactions between the treatments. Differences in fluorescence levels between the different conditions were statistically compared by used an unpaired t-test twosided using the KyPlot software (version 2.0 beta 15, [1997] [1998] [1999] [2000] [2001] Koichi Yoshioka). *Po0.05 and **Po0.01.
Note added: A recent paper showed that by using an empirical electrically mediated siRNA transfer the silencing of the Mitf gene in mice tumors can bring a temporary reduction in the outgrowth of subcutaneaous melanoma. 46 
